Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Construction in Progress (2020 - 2022)

Marker Therapeutics (MRKR) has disclosed Construction in Progress for 3 consecutive years, with $4.1 million as the latest value for Q1 2022.

  • Quarterly Construction in Progress changed N/A to $4.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Mar 2022, changed N/A year-over-year, with the annual reading at $2.2 million for FY2021, 67.26% down from the prior year.
  • Construction in Progress for Q1 2022 was $4.1 million at Marker Therapeutics, up from $2.2 million in the prior quarter.
  • The five-year high for Construction in Progress was $6.8 million in Q4 2020, with the low at $2.2 million in Q3 2021.
  • Average Construction in Progress over 3 years is $3.8 million, with a median of $3.4 million recorded in 2020.
  • Peak annual rise in Construction in Progress hit 51.73% in 2021, while the deepest fall reached 67.26% in 2021.
  • Over 3 years, Construction in Progress stood at $6.8 million in 2020, then crashed by 67.26% to $2.2 million in 2021, then soared by 83.7% to $4.1 million in 2022.
  • According to Business Quant data, Construction in Progress over the past three periods came in at $4.1 million, $2.2 million, and $2.2 million for Q1 2022, Q4 2021, and Q3 2021 respectively.